MedTrace Logo

Heme Arginate in Functional Magnetic Resonance Imaging (fMRI)

NCT01461512 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-10-28

No results posted yet for this study

Summary

Ischemia reperfusion injury may be attenuated by HO-1 induction. Heme arginate showed protective effects during prolonged ischemia in animal studies. Functional blood oxygen level dependent (BOLD) magnetic resonance imaging (MRI) shall evaluate the effects of HO-1 induction during short-time ischemia in skeletal muscle of healthy subjects.

Conditions

  • Ischemia-reperfusion Injury

Interventions

DRUG

heme arginate administration

heme arginate 1 mg/kg body weight 24 hours prior to ischemia

DRUG

Placebo administration

NaCl isotonic

Sponsors & Collaborators

  • MWolzt

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
46 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-08-31
Completion
2011-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01461512 on ClinicalTrials.gov